Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002478 · ClinicalTrials.gov registry record · Phase 2

Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer

A Phase 2 study, sponsored by Gynecologic Oncology Group.

Terminated
Registry status
Phase 2
Development phase

NCT00002478 is a Phase 2 study that was terminated before completion, run by Gynecologic Oncology Group.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002478, a Phase 2 study, was terminated before completion, sponsored by Gynecologic Oncology Group.

TERMINATED
Registry status
Phase 2
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of etoposide in treating patients who have refractory, recurrent, or metastatic ovarian or cervical cancer.

Interventions

  • DRUG etoposide

Trial Details

FieldValue
Start Date 1993-06
Phase Phase 2

Sponsor

Gynecologic Oncology Group

154 total trials

What the Registry Record Tells You About NCT00002478

The ClinicalTrials.gov registry entry for NCT00002478 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which etoposide is the first listed.

NCT00002478 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00002478 about?

NCT00002478 is a clinical study titled "Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of etoposide in treating patients who have refractory, recurrent, or metastatic ovarian or cervical cancer.

What is the current status of trial NCT00002478?

This trial is currently terminated. It is a Phase 2 study. The study started on 1993-06.

What interventions are being tested in trial NCT00002478?

The interventions under investigation include: etoposide (DRUG).

Who is sponsoring clinical trial NCT00002478?

This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.